Adenosine-d13
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No


Adenosine-d13
Description:
Adenosine-d13 (Adenine riboside-d13; D-Adenosine-d13) is deuterium labeled Adenosine (HY-B0228) . Adenosine (Adenine riboside), a ubiquitous endogenous autacoid, acts through the enrollment of four G protein-coupled receptors: A1, A2A, A2B, and A3. Adenosine affects almost all aspects of cellular physiology, including neuronal activity, vascular function, platelet aggregation, and blood cell regulation.Product Name Alternative:
Adenine riboside-d13; D-Adenosine-d13UNSPSC:
12352005Target:
Apoptosis; Autophagy; Endogenous Metabolite; Isotope-Labeled Compounds; Nucleoside Antimetabolite/AnalogType:
Isotope-Labeled CompoundsRelated Pathways:
Apoptosis; Autophagy; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; OthersApplications:
Metabolism-protein/nucleotide metabolismField of Research:
Cancer; Metabolic DiseasePurity:
96.6Solubility:
10 mM in DMSOSmiles:
[2H]N ([2H]) C1=NC ([2H]) =NC2=C1N=C ([2H]) N2[C@]3 ([2H]) O[C@@] (C ([2H]) ([2H]) O[2H]) ([2H]) [C@] (O[2H]) ([2H]) [C@]3 ([2H]) O[2H]Molecular Formula:
C10D13N5O4Molecular Weight:
280.32References & Citations:
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53 (2) :211-216.|[2]Zhou XT, et al. Inhibition of autophagy enhances adenosine induced apoptosis in human hepatoblastoma HepG2 cells. Oncol Rep. 2019;41 (2) :829-838.|[3]Eltzschig HK. Adenosine: an old drug newly discovered. Anesthesiology. 2009;111 (4) :904-915.|[4]Borea PA, Gessi S, Merighi S, Vincenzi F, Varani K. Pharmacology of Adenosine Receptors: The State of the Art. Physiol Rev. 2018;98 (3) :1591-1625.|[5]Fredholm BB. Adenosine, an endogenous distress signal, modulates tissue damage and repair. Cell Death Differ. 2007;14 (7) :1315-1323.Shipping Conditions:
Room TemperatureStorage Conditions:
-20°C, 3 years; 4°C, 2 years (Powder)Scientific Category:
Isotope-Labeled CompoundsClinical Information:
No Development Reported
